Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type ...

Corcept Therapeutics said on Monday its experimental combination ovarian cancer drug improved survival in patients with a ...

A common blood test for ovarian cancer is more likely to fall short for Black and Native American women, according to a new ...

She believed that had she had a CA125 blood test earlier - CA125 is a protein in the blood and can be raised in women with ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

A comparison of patients with and without BRCA gene mutations receiving prophylactic risk-reduction surgery suggest ...

The ROSELLA study evaluating Corcept's relacorilant plus nab-paclitaxel for treating patients with platinum-resistant ovarian ...

Corcept's Phase III trial of relacorilant with nab-paclitaxel has met its primary endpoint, demonstrating an improvement in ...

Northwestern Medicine scientists have uncovered new details about the genetic structure of ovarian cancer stem cells, ...

The phase 3 trial showed relacorilant with chemotherapy improved progression-free and overall survival in platinum-resistant ...

Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to ...

STORY: A U.S. judge has rejected Johnson & Johnson’s $10 billion bid to settle lawsuits claiming its talc products caused ...